Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways

W Luo, Y Gu, S Fu, J Wang, J Zhang, Y Wang - European Journal of …, 2023 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is the most common fibrotic form of idiopathic diffuse lung
disease. Due to limited treatment options, IPF patients suffer from poor survival. About ten …

Discoidin domain receptor inhibitors as anticancer agents: A systematic review on recent development of DDRs inhibitors, their resistance and structure activity …

GP Shenoy, R Pal, GSP Matada, E Singh… - Bioorganic …, 2023 - Elsevier
Discoidin domain receptors (DDRs) are one of the less explored targets for the treatment of
cancer which belong to receptor tyrosine kinases family. Discoidin domain receptors (DDRs) …

Design, synthesis, and biological evaluation of novel discoidin domain receptor inhibitors for the treatment of lung adenocarcinoma and pulmonary fibrosis

S Liu, X Li, C Chen, X Lin, W Zuo, C Peng… - European Journal of …, 2024 - Elsevier
Discoidin domain receptors (DDR) play crucial roles in cell proliferation and differentiation.
When DDRs are overexpressed, it has been associated with various diseases such as …

Research progress of DDR1 inhibitors in the treatment of multiple human diseases

M Liu, J Zhang, X Li, Y Wang - European Journal of Medicinal Chemistry, 2024 - Elsevier
Abstract Discoidin domain receptor 1 (DDR1) is a collagen-activated receptor tyrosine
kinase (RTK) and plays pivotal roles in regulating cellular functions such as proliferation …